Company Filing History:
Years Active: 2007
Title: Jen-Liang Su: Innovator in Biomedicine
Introduction
Jen-Liang Su is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of biomedicine, particularly through his innovative research and development of therapeutic peptides.
Latest Patents
One of his notable patents is titled "Oligopeptide antagonist of interleukin-6." This invention provides an antagonist peptide of interleukin-6 (IL-6), which comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7. The peptide is designed to specifically bind to IL-6R, competing for the binding of IL-6 to IL-6R. This mechanism effectively blocks IL-6-induced signal transduction, inhibiting IL-6-mediated anti-apoptosis and angiogenesis, and further suppressing IL-6-mediated tumor growth. Jen-Liang Su holds 1 patent for this groundbreaking work.
Career Highlights
Jen-Liang Su is affiliated with National Taiwan University, where he continues to advance his research in the biomedical field. His work has garnered attention for its potential applications in cancer therapy and other medical treatments.
Collaborations
He has collaborated with notable colleagues, including Lin-Hung Wei and Min-Liang Kuo, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Jen-Liang Su's contributions to biomedicine through his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to impact cancer treatment and improve patient outcomes significantly.